MGC Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MXC.AX research report →
Price Chart
About the company
MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms.
- CEO
- Roby Reuven Zomer
- IPO
- 2006
- HQ
- West Perth, WA, AU
Get TickerSpark's AI analysis on MXC.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.42M
- P/E
- -0.06
- PEG
- -0.00
- P/S
- 5.44
- P/B
- -0.17
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
- Gross Margin
- 37.96%
- Op Margin
- -457.29%
- Net Margin
- -614.64%
- ROE
- 2660.08%
- ROIC
- -257.29%
Latest fiscal year · YoY change
- Revenue
- $3.39M-28.4%
- Gross Profit
- $1.29M-17.7%
- Op Income
- $-15,493,000
- Net Income
- $-20,824,000-2.3%
- EPS
- $-7.10+10.1%
- OCF Growth
- +1.4%
- FCF Growth
- +18.0%
- 52W High
- $11.00
- 52W Low
- $0.30
- 50D MA
- $0.41
- 200D MA
- $1.52
- Beta
- 1.03
- RSI (14)
- 48
- Avg Volume
- 21.34K
No earnings-call transcripts are available for MXC.AX yet.
- Free Float
- 47.6%
- Shares Outstanding
- 43.85M
- Float Shares
- 20.86M
Our MXC.AX coverage
Recent articles, reports, and earnings notes.
No research on MXC.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MXC.AX report →